Agios Pharmaceuticals, Inc.
AGIO
$34.41
-$1.09-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.29M | -96.52M | 947.92M | -96.12M | -81.55M |
| Total Depreciation and Amortization | 1.28M | 1.37M | 1.35M | 1.59M | 1.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.03M | 8.25M | -1.08B | 11.81M | 9.32M |
| Change in Net Operating Assets | -36.51M | -46.26M | 45.35M | 10.13M | -28.99M |
| Cash from Operations | -111.49M | -133.17M | -84.22M | -72.59M | -99.87M |
| Capital Expenditure | -766.00K | -967.00K | -419.00K | -158.00K | -141.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 0.00 | 40.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 200.00M | -- | -- |
| Other Investing Activities | 113.35M | -48.19M | 51.21M | 37.40M | 124.66M |
| Cash from Investing | 112.59M | -49.16M | 250.79M | 37.24M | 124.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.62M | 4.84M | 2.64M | 1.10M | 5.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.62M | 4.84M | 2.64M | 1.10M | 5.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.72M | -177.48M | 169.21M | -34.25M | 30.56M |